BioSpace News Archive

Scorpion Biological Services, a fully integrated contract research and contract development & manufacturing organization focused on the development of biologic drugs, hosted the grand opening of its new, state-of-the-art San Antonio facility on Friday, October 21, 2022.

Nihon Medi-Physics Co., Ltd. is pleased to announce that the U.S. Food and Drug Administration has recently accepted NMP’s Investigational New Drug application to initiate a first-in-human phase I clinical study of “NMK89,” which is an imaging agent currently developed for cancer diagnostic use in cancer theranostics.

Inotrem announced at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress.

Dutch/Swiss biotech company Micreos announced it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that it has signed a distribution agreement with Science - Link Trading, a company whose mission it is to help bring new disruptive technologies to market.

Mevion Medical Systems is pleased to announce it has entered into a contract with the Froedtert & the Medical College of Wisconsin health network to bring the MEVION S250i Proton Therapy System® to Wisconsin.

Precision Genomics is pleased to announce that our new mRNA technology may offer a solution to assist in the diagnosis of and establish treatment protocols for, the current healthcare crisis, Long Covid.

iSpecimen Inc. today announced that it will report its financial results for the third quarter ended September 30, 2022, before the markets open on Tuesday, November 8, 2022.

OpGen, Inc. and BioVersys AG today announced the signing of a collaboration agreement for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100.

Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financial market opens on November 8, 2022.